Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 5
Submit an article Journal homepage
235
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluation

Safety and efficacy of tenecteplase in acute myocardial infarction

Daniel R Guerra Department of Medicine, Brigham Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. [email protected]
,
Juhana Karha Department of Medicine, Brigham Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. [email protected]
&
C Michael Gibson Department of Medicine, Brigham Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. [email protected]
Pages 791-798 | Published online: 02 Mar 2005

Bibliography

  • BRAUNWALD E: The open artery theory is alive and well again. N Engl. J. Med. (1993) 329:1650–1652.
  • The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N. Engl. J. Med. (1993) 329:1615–1622.
  • A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. GUSTO IIb investigators. N. Engl. J. Med. (1997) 336:1621–1628.
  • GRINES CL, BROWNE KF, MARCO J et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl. J. Med. (1993) 328:673–679.
  • DE BOER MJ, HOORNTJE JC, OTTERVANGER JP, REIFFERS S, SURYAPRANATA H: Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. film. Coll Cardiol. (1994) 23:1004–1008.
  • WEAVER WD, SIMES RJ, BETRIU A et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 278:2093–2098.
  • RYAN TJ, ANTMAN EM, BROOKS NHet al: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll Cardiol (1999) 34:890–911.
  • Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet (1994) 343:311–322.
  • BERKOWITZ SD, GRANGER CB, PIEPER KS et al: Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded coronary arteries (GUSTO) I investigators. Circulation (1997) 95:2508–2516.
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl. J. Med. (1993) 329:673–682.
  • LLEVADOT J, GIUGLIANO RP, ANTMAN EM: Bolus fibrinolytic therapy in acute myocardial infarction. JAMA (2001) 286:442–449.
  • KEYT BA, PAONI NE REFINO CJ et al: A faster-acting and more potent form of tissue plasminogen activator. Proc. Natl. Acad. Sci. USA (1994) 91:3670–3674.
  • PAONI NE KEYT BA, REFINO CJ et al: A slow clearing, fibrin-specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299 AAAA). Thromb. Haemost. (1993) 70:307–312.
  • GIBSON CM, MARBLE SJ: Issues in theassessment of the safety and efficacy of tenecteplase (TNK-tPA). Chit. Cardiol. (2001) 24:577–584.
  • BENEDICT CR, REFINO CJ, KEYT BA et al.: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation (1995) 92:3032–3040.
  • CANNON CP, MCCABE CH, GIBSON CM et al.: TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation (1997) 95:351–356.
  • MUELLER HS, RAO AK, FORMAN SA: Thrombolysis In Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J. Am. Coll Cardiol. (1987) 10:479–490.
  • VANDESCHUEREN S, BARRIOS L, KERDSINCHAI P et al: A recombinant trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation (1995) 92:2044–2049.
  • MODI NB, FOX NL, CLOW FW et al:Pharmacokinetics and pharmacodynamics of tenecteplase: results from a Phase II study in patients with acute myocardial infarction. J. Chit. Pharmacol. (2000) 40:508–515.
  • CANNON CP, GIBSON CM, MCCABE CH et al: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation (1998) 98:2805–2814.
  • GIUGLIANO RP, CANNON CP, MCCABE CH, VAN DE WERF F, BRAUNWALD E: Lower-dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: results from TIMI 10B and ASSENT 1. Circulation (1997) 96:1–535.
  • GIBSON CM, CANNON CP, MURPHY SA et al.: Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am. J. Cardiol (1999) 84:976–980.
  • GIBSON CM, MURPHY SA, RIZZO MJ et al.: Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 99:1945–1950.
  • WANG-CLOW F, FOX NL, CANNON CP et al.: Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am. Heart. 1 (2001) 141:33-40.
  • GIBSON CM, CANNON CP MURPHY SA, MARBLE SJ, BARRON HV, BRAUNWALD E: Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation (2002) 105:1909–1913.
  • VAN DE WERF E CANNON CP, LUYTEN A et al.: Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am. Heart 1. (1999) 137:786–791.
  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet (1999) 354:716–722.
  • A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl. I Med. (1997) 337:1118–1123.
  • CANNON CP: Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am. J. Cardiol (2000) 85:17C–22C.
  • ALEXANDER J, LI X, CHIN R: Safety and efficacy of 50 mg of TNK-tPA in patients with acute myocardial infarction: results from ASSENT-2. Circulation (2000) 102:11–258.
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605–613.
  • ANTMAN EM, LOUWERENBURG HW, BAARS HF et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation (2002) 105: 1642-1649.
  • Prehospital thrombolytic therapy in patientswith suspected acute myocardial infarction. The European Myocardial Infarction Project Group. N Erigl. J. Med. (1993) 329:383–389.
  • RAWLES J, FOR THE GREAT GROUP: Halving of mortality at one year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J. Am. Coll Cardiol (1994) 23:1–5.
  • WALLENTIN L: The ASSENT-3 pre-hospitalization satellite study, presented on behalf of ASSENT-3 PLUS investigators. 79' Scientific Sessions of the American Heart Association, Chicago, USA (2002).
  • ARMSTRONG PW, GRANGER C, VAN DE WERF F: Bolus fibrinolysis: risk, benefit, and opportunities. Circulation (2001) 103:1171–1173.
  • Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet (1995) 346:329–336.
  • GURWITZ JH, GORE JM, GOLDBERG RJ et al: Risk for intra-cranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann. Intern. Med. (1998) 129:597–604.
  • VAN DE WERF F, BARRON HV, ARMSTRONG PW et al.: Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur. Heart J. (2001) 22:2253–2261.
  • THIEMANN DR, CORESH J, SCHULMAN SP, GERSTENBLITH G: Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation (2000) 101:2239–2246.
  • AYANIAN JZ, BRAUNWALD E: Thrombolytic therapy for patients with myocardial infarction who are older than 75 years: do the risks outweigh the benefits? Circulation (2000) 101:2224.
  • ANTMAN EM, WILCOX RG, GIUGLIANO RP et al: Long-Term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 Month follow-up in the TIME-II trial. Circulation (1999) 100:1–498.
  • MURPHY SA, GIBSON CM, VAN DE WERF F: Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT-1). Am. J. Cardiol (2002) 90:51–54.
  • GIBSON CM: Weight-adjusted dosing of fibrinolytic agents. The good and the bad. 73m Scientific Sessions of the American Heart Association, New Orleans, USA (2000).
  • ANGEJA BG, ALEXANDER JH, CHIN R et al.: Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am. 1. Cardiol (2001) 88:1240–1245.

Websites

  • www.americanheartorg/downloadable/heart/ 1023898043312CVD_stats.pdf American Heart Association website (2002).
  • http://www.gene.com/gene/products/ information/cardiovascularhnkase/insertjsp TNKase prescribing information. Genentech Inc., South San Francisco, CA, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.